Dec 04, 2018 28 (6) 813-815
Vol. 28, Issue 6, Medline Page 813-815
Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes?
Heart failure and renal disease remain significant complications in people with type 2 diabetes (T2D). Recent outcome studies with sodium-glucose cotransporter-2 (SGLT2) inhibitors have provided increasing insights, with the latest reporting trial DECLARE-TIMI 58 (Wiviott et al., 2018), pointing toward a role for these agents in the primary prevention of cardio-renal complications in T2D.